Robert J. Gray
Dana-Farber Cancer Institute · 355 works · 25,441 citations · h-index 62
Top works
- A Proportional Hazards Model for the Subdistribution of a Competing Risk
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Computing an Exact Confidence Interval for the Common Odds Ratio in Several 2×2 Contingency Tables
- Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System
- Efficacy of Adjuvant Chemotherapy in High-Risk Node-Negative Breast Cancer
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- Flexible Methods for Analyzing Survival Data Using Splines, With Applications to Breast Cancer Prognosis
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- Annual hazard rates of recurrence for breast cancer after primary therapy.
- Construction of Receiver Operating Characteristic Curves when Disease Verification Is Subject to Selection Bias
- Some Diagnostic Methods for Cox Regression Models Through Hazard Smoothing
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
- Calculation of polychotomous logistic regression parameters using individualized regressions
- Bayesian Models for Gene Expression With DNA Microarray Data
- Locoregional Failure 10 Years After Mastectomy and Adjuvant Chemotherapy With or Without Tamoxifen Without Irradiation: Experience of the Eastern Cooperative Oncology Group
- Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory
- Spline-Based Tests in Survival Analysis
- Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy.
- Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer